TG Therapeutics (TGTX) Stock Price, News & Analysis

TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company is closely associated with the development and commercialization of BRIUMVI (ublituximab-xiiy), a monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). TG Therapeutics’ common stock trades on the Nasdaq Capital Market under the symbol TGTX.

Core business and therapeutic focus

According to company disclosures, TG Therapeutics is a fully integrated biopharmaceutical organization concentrating on B-cell–directed therapies. Its primary commercial product is BRIUMVI, which targets CD20-expressing B-cells. The company describes BRIUMVI as a novel monoclonal antibody that binds a unique epitope on CD20 and is glycoengineered to lack certain sugar molecules normally expressed on the antibody. This glycoengineering is intended to allow efficient B-cell depletion at low doses.

BRIUMVI is indicated in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Company communications also state that BRIUMVI has been approved by several regulatory agencies outside the U.S. for adult patients with RMS who have active disease defined by clinical or imaging features. TG Therapeutics reports that it generates a majority of its revenue from BRIUMVI sales in the United States, with additional revenue from sales in other countries and from ex-U.S. partners.

BRIUMVI and multiple sclerosis

Relapsing multiple sclerosis is described by the company as a chronic demyelinating disease of the central nervous system that includes relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis with continued relapses. TG Therapeutics highlights BRIUMVI’s role as an anti-CD20 B-cell–depleting therapy for RMS. Clinical trial information released by the company notes that BRIUMVI is administered as an intravenous infusion and that its regimen involves a starting dose followed by infusions given twice a year.

The company has reported data from the ULTIMATE I & II Phase 3 trials and their open-label extension, in which patients with RMS were treated with BRIUMVI. TG Therapeutics states that after six years of continuous BRIUMVI treatment, a high proportion of patients remained free from 24-week confirmed disability progression, and that annualized relapse rates decreased over time in these long-term data. The overall safety profile in these analyses was described as consistent over prolonged treatment, with no new safety signals emerging in the exposure-adjusted analysis of adverse events.

Pipeline and development programs

Beyond its approved therapy, TG Therapeutics reports a research pipeline that includes several investigational medicines for B-cell disorders and autoimmune disease. The company has described development programs for:

• Subcutaneous BRIUMVI (ublituximab), being evaluated in a Phase 3 pivotal program.
• A simplified intravenous dosing schedule for BRIUMVI, studied in the Phase 3 ENHANCE trial, which compares a consolidated Day 1 and Day 15 dosing regimen with the existing approved regimen.
• Azer-cel, identified by the company as an allogeneic CD19 CAR T therapy being evaluated in a Phase 1 clinical trial for autoimmune diseases, including progressive forms of multiple sclerosis.

In addition, prior descriptions of the pipeline reference investigational candidates such as TG-1701 (a BTK inhibitor) and TG-1801 (an anti-CD47/CD19 bispecific monoclonal antibody) for B-cell disorders. These programs are characterized by the company as being in early-stage clinical development.

Commercialization and geographic reach

TG Therapeutics states that it is a commercial-stage company, with BRIUMVI revenues driving its growth. Revenue disclosures indicate that product revenue consists primarily of net product sales of BRIUMVI in the United States, along with sales to an ex-U.S. licensing partner. Company updates note that BRIUMVI has received approvals in regions including the European Union, the United Kingdom, Switzerland, Australia, and several other countries for RMS with active disease defined by clinical or imaging features. The company also reports license, milestone, royalty, and other revenue associated with its ex-U.S. commercialization agreements.

The company has highlighted participation in major healthcare and biotechnology investor conferences, as well as inclusion in rankings such as the Deloitte Technology Fast 500 list, attributing its growth to BRIUMVI revenues following U.S. approval for relapsing forms of multiple sclerosis.

Clinical data and real-world evidence

Through press releases and scientific meeting presentations, TG Therapeutics has outlined multiple data sets supporting BRIUMVI in RMS:

• ULTIMATE I & II Phase 3 trials: randomized, double-blind, active comparator–controlled studies in patients with RMS treated for 96 weeks, comparing BRIUMVI to teriflunomide. Patients received BRIUMVI infusions on a schedule that included an initial 150 mg infusion, a 450 mg infusion two weeks later, and subsequent 450 mg infusions every 24 weeks.
• Six-year open-label extension data: company summaries report low and decreasing annualized relapse rates over years 3 through 6 of continuous BRIUMVI treatment, a high proportion of patients free from confirmed disability progression, and stable immunoglobulin levels with no association between decreased immunoglobulins and serious infection risk in the reported analysis.
• ENHANCE trial: a Phase 3b randomized, double-blind, placebo-controlled study evaluating a modified IV BRIUMVI regimen. The trial compares a single 600 mg Day 1 infusion followed by a placebo infusion on Day 15 and a later infusion, versus the standard split-dosing regimen. The primary endpoint is non-inferior exposure with respect to area under the curve at week 16.
• ENABLE observational study: a Phase 4 real-world observational study of patients with RMS initiating ublituximab. Company-reported data describe on-treatment annualized relapse rates that were low in this real-world cohort, with most participants experiencing no relapses and infusion durations consistent with expected times.

Safety profile and risk information

Company materials provide detailed safety information for BRIUMVI. Key elements include:

• Contraindications in patients with active Hepatitis B virus infection and in those with a history of life-threatening infusion reaction to BRIUMVI.
• Infusion reactions, which may include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and anaphylactic reactions. The company states that infusion reactions occurred in a substantial proportion of BRIUMVI-treated patients in MS clinical trials, with a small percentage experiencing serious reactions.
• Infections, including serious, life-threatening, or fatal bacterial and viral infections. The company notes overall infection rates and serious infection rates in BRIUMVI-treated patients compared with teriflunomide-treated patients in clinical trials, with upper respiratory tract infection and urinary tract infection among the most common infections.
• Hepatitis B virus reactivation, with guidance to screen all patients for HBV prior to initiation and to avoid treatment in patients with active HBV.
• Progressive multifocal leukoencephalopathy (PML) as a potential risk associated with anti-CD20 antibodies and other MS therapies, although no PML cases have been reported in BRIUMVI-treated MS patients in the company’s data.
• Vaccinations, including recommendations for timing of live and non-live vaccines relative to BRIUMVI treatment and cautions regarding vaccination of infants born to mothers treated with BRIUMVI during pregnancy.
• Fetal risk based on animal data indicating potential harm when administered during pregnancy, and guidance for contraception during treatment and for a period after the last dose.
• Reduction in immunoglobulins, with observed decreases in immunoglobulin M and recommendations to monitor quantitative serum immunoglobulin levels and consider discontinuing therapy in certain cases.
• Liver injury, including reports of clinically significant liver injury in the postmarketing setting with anti-CD20 B-cell–depleting therapies approved for MS, and guidance to monitor liver function tests and discontinue BRIUMVI if drug-induced liver injury is suspected.

The most common adverse reactions in RMS trials, as reported by the company, include infusion reactions and upper respiratory tract infections.

Regulatory filings and public company status

TG Therapeutics files reports with the U.S. Securities and Exchange Commission (SEC) as a public company. Recent Form 8-K filings reference press releases announcing financial results for quarterly periods and provide details on product revenue, research and development expenses, selling, general and administrative expenses, and net income. These filings also confirm that the company’s common stock, under the symbol TGTX, is listed on the Nasdaq Capital Market.

Position within the pharmaceutical preparation manufacturing sector

Within the broader pharmaceutical preparation manufacturing and biopharmaceutical sector, TG Therapeutics is characterized in its own materials as a company centered on B-cell diseases and autoimmune conditions, particularly multiple sclerosis. Its focus on monoclonal antibodies targeting CD20-expressing B-cells, and on related investigational therapies such as allogeneic CAR T-cell approaches, reflects a concentration on immune-mediated disease mechanisms. The company’s operations span clinical development, regulatory interactions, and commercial distribution of its approved therapy, with additional activities in clinical research and ex-U.S. partnering.

Investor considerations

Investors researching TGTX can observe from company disclosures that revenue is currently driven largely by BRIUMVI product sales and related ex-U.S. arrangements, while research and development spending supports clinical trials for new formulations, dosing regimens, and pipeline candidates. Public communications also reference share repurchase programs authorized by the company’s board of directors, as well as participation in healthcare and biotechnology investor conferences.